Pub Date : 2023-11-30DOI: 10.3332/ecancer.2023.1642
Gebrekirstos Hagos, Nazik Hammad, Susannah Stanway, A. Yusuf, Tekleberhan Hailemariam
Somaliland is an autonomous region in the northern part of Somalia that declared its independence in 1991. It is a low-income country (LIC) with a population size of 5.7 million with a gross domestic product per capita of $775. Health services are delivered by public, private and non-governmental organisations. The public health care system in Somaliland is facing huge challenges. Seven percent of the population suffers from non-communicable diseases, but data on cancer incidence and mortality are not available. Much of the emphasis in public health has been placed on primary care and maternal and child health. There is still a large gap in cancer prevention, early detection and screening in the country. Additionally, there is no cancer registry or published data on cancer. Currently, there are a few private hospitals that provide chemotherapy services in Somaliland of which Needle Hospital is one. Services provided in this hospital include medical oncology for all solid tumours, palliative care, follow-up and cancer health education. The hospital provides services for patients from Somaliland and neighbouring countries including Djibouti, Somalia and Ethiopia. As a new oncology clinic in an LIC, the clinic is facing many challenges, like the absence of a multidisciplinary tumour board, presentation of patients at the advanced stage of tumours and poor cancer awareness in the general population.
{"title":"Cancer care in Needle Hospital, Hargeisa, Somaliland","authors":"Gebrekirstos Hagos, Nazik Hammad, Susannah Stanway, A. Yusuf, Tekleberhan Hailemariam","doi":"10.3332/ecancer.2023.1642","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1642","url":null,"abstract":"Somaliland is an autonomous region in the northern part of Somalia that declared its independence in 1991. It is a low-income country (LIC) with a population size of 5.7 million with a gross domestic product per capita of $775. Health services are delivered by public, private and non-governmental organisations. The public health care system in Somaliland is facing huge challenges. Seven percent of the population suffers from non-communicable diseases, but data on cancer incidence and mortality are not available. Much of the emphasis in public health has been placed on primary care and maternal and child health. There is still a large gap in cancer prevention, early detection and screening in the country. Additionally, there is no cancer registry or published data on cancer. Currently, there are a few private hospitals that provide chemotherapy services in Somaliland of which Needle Hospital is one. Services provided in this hospital include medical oncology for all solid tumours, palliative care, follow-up and cancer health education. The hospital provides services for patients from Somaliland and neighbouring countries including Djibouti, Somalia and Ethiopia. As a new oncology clinic in an LIC, the clinic is facing many challenges, like the absence of a multidisciplinary tumour board, presentation of patients at the advanced stage of tumours and poor cancer awareness in the general population.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"77 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139206967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-30DOI: 10.3332/ecancer.2023.1643
Nicolás Duque Clavijo, Paula A Lara, John Alejandro Murillo Silva, I. Triana, H. A. Vargas, Luis Eduardo Pino, Javier Mauricio Segovia, Erick Andrés Cantor
In Colombia, renal cancer is a rare condition, with clear cell renal cell carcinoma (ccRCC) being the most prevalent neoplasm. In recent years, immune checkpoint inhibitors (ICI) have been proposed for the management of metastatic disease, as they have shown improved rates of response and long-term survival. Furthermore, they exhibit a favourable tolerance profile, and adverse events causing significant morbidity are infrequent. We report the case of a 61-year-old male patient initially diagnosed with early-stage ccRCC who underwent right nephrectomy in 2009. Six years later, disease recurrence with metastatic compromise was documented, which led to the resection of the L1 vertebral body followed by radiotherapy and maintenance treatment with sunitinib. Due to disease progression, treatment with sunitinib was discontinued. Subsequently, evero-limus was initiated as second-line immunotherapy, which was later discontinued due to the appearance of new metastatic lesions. In 2017, the patient was referred to our institution, where a third-line pharmacological treatment with nivolumab was initiated. In 2022, complete remission by positron emission tomography-computed tomography (PET-CT) was evidenced, which has been sustained to date. This case demonstrates the efficacy and safety of ICI in patients with metastatic ccRCC. The case presented is relevant in that it describes the achievement of complete remission in a patient who did not respond to the first two lines of immunotherapy. Given the limited literature regarding the discontinuation of therapy after achieving sustained remission, further research is warranted to explore this topic.
{"title":"Successful long-term management of metastatic clear cell renal cell carcinoma with nivolumab: a case report and literature review","authors":"Nicolás Duque Clavijo, Paula A Lara, John Alejandro Murillo Silva, I. Triana, H. A. Vargas, Luis Eduardo Pino, Javier Mauricio Segovia, Erick Andrés Cantor","doi":"10.3332/ecancer.2023.1643","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1643","url":null,"abstract":"In Colombia, renal cancer is a rare condition, with clear cell renal cell carcinoma (ccRCC) being the most prevalent neoplasm. In recent years, immune checkpoint inhibitors (ICI) have been proposed for the management of metastatic disease, as they have shown improved rates of response and long-term survival. Furthermore, they exhibit a favourable tolerance profile, and adverse events causing significant morbidity are infrequent. We report the case of a 61-year-old male patient initially diagnosed with early-stage ccRCC who underwent right nephrectomy in 2009. Six years later, disease recurrence with metastatic compromise was documented, which led to the resection of the L1 vertebral body followed by radiotherapy and maintenance treatment with sunitinib. Due to disease progression, treatment with sunitinib was discontinued. Subsequently, evero-limus was initiated as second-line immunotherapy, which was later discontinued due to the appearance of new metastatic lesions. In 2017, the patient was referred to our institution, where a third-line pharmacological treatment with nivolumab was initiated. In 2022, complete remission by positron emission tomography-computed tomography (PET-CT) was evidenced, which has been sustained to date. This case demonstrates the efficacy and safety of ICI in patients with metastatic ccRCC. The case presented is relevant in that it describes the achievement of complete remission in a patient who did not respond to the first two lines of immunotherapy. Given the limited literature regarding the discontinuation of therapy after achieving sustained remission, further research is warranted to explore this topic.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":" 29","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139207156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-27DOI: 10.3332/ecancer.2023.1641
D. Sweed, Shaymaa Sabry El Gammal, S. Kilany, S. Abdelsattar, Sara Mohamed Abd Elhamed
Background: The most common types of primary malignant liver tumours are hepato-cellular carcinoma (HCC) and cholangiocarcinoma (CCA). Treatment options for patients who are inoperable/advanced, or recurring are challenging. Cyclin D1, epidermal growth factor (EGFR) and vascular endothelial growth factor (VEGR) are common carcinogenic proteins that have potential therapeutic targets in various cancers. They have been implicated in the development of HCC and CCA. In this study, we aimed to evaluate the oncogenic function expression of cyclin D1, EGFR and VEGF in HCC and CCA of Egyptian patients. This could help to validate their therapeutic potential. Material and methods: Tumour cases were selected from 82 cases of primary liver carcinomas, with 58 cases being from HCC and 24 cases from CCA compared to 51 non-tumour adjacent liver cases and 18 from normal liver tissue. The immunohistochemical study of cyclin D1, EGFR and VEGR was conducted. Results: Cyclin D1, EGFR and VEGF are overexpressed in HCC and CCA as compared to the control group ( p < 0.001). Cyclin D1 was related to well-differentiated grade and early pathologic stage in HCC ( p = 0.016 and p = 0.042, respectively). The well-differentiated grade showed significantly higher VEGF levels ( p = 0.04). In the CCA group, however, EGFR was strongly related to high tumour size ( p = 0.047). EGFR and VEGF were over-expressed in HCC raised in the non-cirrhotic liver compared to those developed in post-hepatitic liver cirrhosis ( p = 0.003 and p = 0.014). Conclusion: Cyclin D1, EGFR and VEGF shared significant overexpression in HCC and CCA. EGFR and VEGF may play an oncogenic function in the development of HCC in non-cirrhotic liver. Furthermore, cyclin D1 and VEGF may play a good prognostic function in HCC, but EGFR may play a bad prognostic role in CCA.
背景：最常见的原发性恶性肝肿瘤是肝细胞癌（HCC）和胆管癌（CCA）。无法手术/晚期或复发患者的治疗方案具有挑战性。细胞周期蛋白 D1、表皮生长因子（EGFR）和血管内皮生长因子（VEGR）是常见的致癌蛋白，是各种癌症的潜在治疗靶点。它们被认为与 HCC 和 CCA 的发展有关。本研究旨在评估细胞周期蛋白 D1、表皮生长因子受体和血管内皮生长因子在埃及 HCC 和 CCA 患者中的致癌功能表达。这有助于验证它们的治疗潜力。材料和方法：肿瘤病例选自 82 例原发性肝癌，其中 58 例来自 HCC，24 例来自 CCA，而非肿瘤邻近肝脏病例 51 例，正常肝组织 18 例。对细胞周期蛋白 D1、表皮生长因子受体（EGFR）和血管内皮生长因子受体（VEGR）进行免疫组化研究。结果显示与对照组相比，细胞周期蛋白 D1、表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）在 HCC 和 CCA 中过表达（P < 0.001）。细胞周期蛋白 D1 与 HCC 的分化程度和早期病理分期有关（分别为 p = 0.016 和 p = 0.042）。分化良好的分级显示血管内皮生长因子水平明显更高（p = 0.04）。然而，在CCA组中，表皮生长因子受体（EGFR）与肿瘤大小密切相关（p = 0.047）。与肝硬化后发生的 HCC 相比，非肝硬化发生的 HCC 表皮生长因子受体和血管内皮生长因子表达过高 ( p = 0.003 和 p = 0.014)。结论细胞周期蛋白 D1、表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）在 HCC 和 CCA 中均显著过表达。表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）可能在非肝硬化的 HCC 发病过程中发挥致癌作用。此外，细胞周期蛋白 D1 和血管内皮生长因子在 HCC 中可能起到良好的预后作用，但表皮生长因子受体在 CCA 中可能起到不良的预后作用。
{"title":"The expression of VEGF and cyclin D1/EGFR in common primary liver carcinomas in Egypt: an immunohistochemical study","authors":"D. Sweed, Shaymaa Sabry El Gammal, S. Kilany, S. Abdelsattar, Sara Mohamed Abd Elhamed","doi":"10.3332/ecancer.2023.1641","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1641","url":null,"abstract":"Background: The most common types of primary malignant liver tumours are hepato-cellular carcinoma (HCC) and cholangiocarcinoma (CCA). Treatment options for patients who are inoperable/advanced, or recurring are challenging. Cyclin D1, epidermal growth factor (EGFR) and vascular endothelial growth factor (VEGR) are common carcinogenic proteins that have potential therapeutic targets in various cancers. They have been implicated in the development of HCC and CCA. In this study, we aimed to evaluate the oncogenic function expression of cyclin D1, EGFR and VEGF in HCC and CCA of Egyptian patients. This could help to validate their therapeutic potential. Material and methods: Tumour cases were selected from 82 cases of primary liver carcinomas, with 58 cases being from HCC and 24 cases from CCA compared to 51 non-tumour adjacent liver cases and 18 from normal liver tissue. The immunohistochemical study of cyclin D1, EGFR and VEGR was conducted. Results: Cyclin D1, EGFR and VEGF are overexpressed in HCC and CCA as compared to the control group ( p < 0.001). Cyclin D1 was related to well-differentiated grade and early pathologic stage in HCC ( p = 0.016 and p = 0.042, respectively). The well-differentiated grade showed significantly higher VEGF levels ( p = 0.04). In the CCA group, however, EGFR was strongly related to high tumour size ( p = 0.047). EGFR and VEGF were over-expressed in HCC raised in the non-cirrhotic liver compared to those developed in post-hepatitic liver cirrhosis ( p = 0.003 and p = 0.014). Conclusion: Cyclin D1, EGFR and VEGF shared significant overexpression in HCC and CCA. EGFR and VEGF may play an oncogenic function in the development of HCC in non-cirrhotic liver. Furthermore, cyclin D1 and VEGF may play a good prognostic function in HCC, but EGFR may play a bad prognostic role in CCA.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139228342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Central nervous system (CNS) metastases are a significant burden in breast cancer (BC). Capecitabine is a frequent choice in this scenario, but data supporting its single-agent activity are scarce. We aimed to evaluate the intracranial efficacy of capecitabine in CNS metastases from BC. Methods: This retrospective cohort included patients with CNS metastases from BC treated with capecitabine at a single centre. Study endpoints were intracranial CNS objective response rate (CNS-ORR), intracranial CNS disease control rate (CNS-DCR), intracranial CNS progression-free survival (CNS-PFS) and overall survival (OS). Results: 209 patients were included; 41.6% hormone receptor-positive HER2-negative (HR + HER2-), 33.9% human epidermal growth factor receptor 2 positive (HER2+), and 26.4% triple-negative breast cancer (TNBC). Radiotherapy was performed in 90.4% and CNS surgery in 27.5%. Among patients accessible for intracranial response, 3-month CNS-ORR and CNS-DCR were 41.6% and 81.2%. CNS-ORR was numerically higher among TNBC (61% versus 38% in HR + HER2-BC and 35% in HER2 + BC) ( p = 0.194). When considering patients who were not evaluable at 3-month as non-responders, the 3-month CNS-ORR was 19.1% (18.4% in HR + HER2, 18.3% in HER2+, and 21.6% in TNBC). Nevertheless, TNBC was associated with lower CNS-PFS ( p < 0.001) and OS ( p < 0.001). Median PFS was 8.3 months in HR + HER2, 5.0 months in HER2+, and 3.0 months in TNBC. Median OS was 8.7, 9.1 and 4.5 months, respectively. Conclusion: Among patients with BC and CNS metastases accessible for intracranial response at 3 months, intracranial activity was observed with capecitabine. These patients have a poor prognosis regardless of the BC subtype, especially in scenarios where newer therapeutic options are unavailable.
{"title":"Activity of capecitabine for central nervous system metastases from breast cancer","authors":"Mariana Carvalho Gouveia, Cassio Murilo Trovo Hidalgo Filho, Raquel Andrade Moreno, Heitor Castelo Branco Rodrigues Alves, Aline Sgnolf Ayres, Laura Testa, Renata Colombo Bonadio","doi":"10.3332/ecancer.2023.1638","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1638","url":null,"abstract":"Purpose: Central nervous system (CNS) metastases are a significant burden in breast cancer (BC). Capecitabine is a frequent choice in this scenario, but data supporting its single-agent activity are scarce. We aimed to evaluate the intracranial efficacy of capecitabine in CNS metastases from BC. Methods: This retrospective cohort included patients with CNS metastases from BC treated with capecitabine at a single centre. Study endpoints were intracranial CNS objective response rate (CNS-ORR), intracranial CNS disease control rate (CNS-DCR), intracranial CNS progression-free survival (CNS-PFS) and overall survival (OS). Results: 209 patients were included; 41.6% hormone receptor-positive HER2-negative (HR + HER2-), 33.9% human epidermal growth factor receptor 2 positive (HER2+), and 26.4% triple-negative breast cancer (TNBC). Radiotherapy was performed in 90.4% and CNS surgery in 27.5%. Among patients accessible for intracranial response, 3-month CNS-ORR and CNS-DCR were 41.6% and 81.2%. CNS-ORR was numerically higher among TNBC (61% versus 38% in HR + HER2-BC and 35% in HER2 + BC) ( p = 0.194). When considering patients who were not evaluable at 3-month as non-responders, the 3-month CNS-ORR was 19.1% (18.4% in HR + HER2, 18.3% in HER2+, and 21.6% in TNBC). Nevertheless, TNBC was associated with lower CNS-PFS ( p < 0.001) and OS ( p < 0.001). Median PFS was 8.3 months in HR + HER2, 5.0 months in HER2+, and 3.0 months in TNBC. Median OS was 8.7, 9.1 and 4.5 months, respectively. Conclusion: Among patients with BC and CNS metastases accessible for intracranial response at 3 months, intracranial activity was observed with capecitabine. These patients have a poor prognosis regardless of the BC subtype, especially in scenarios where newer therapeutic options are unavailable.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139245148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-23DOI: 10.3332/ecancer.2023.1640
Heloisa Resende, T. Rebelatto, Gustavo Werutsky, Gustavo Gossling, Vinícius Aguiar, Guilherme M C Lopes, Biazi R de Assis, Lilian Arruda, Carlos H Barrios
Background: Epidemiological and clinical cancer research is essential to understanding tumour behaviour and developing
背景：癌症的流行病学和临床研究对于了解肿瘤的行为和制定治疗方案至关重要。
{"title":"Current scenario and future perspectives of clinical research in Brazil: a national survey","authors":"Heloisa Resende, T. Rebelatto, Gustavo Werutsky, Gustavo Gossling, Vinícius Aguiar, Guilherme M C Lopes, Biazi R de Assis, Lilian Arruda, Carlos H Barrios","doi":"10.3332/ecancer.2023.1640","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1640","url":null,"abstract":"Background: Epidemiological and clinical cancer research is essential to understanding tumour behaviour and developing","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"1 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139245658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-23DOI: 10.3332/ecancer.2023.1639
R. V. Yap, Deanne Lou Marquez, Frances Marion De La Serna
Background: In the 2020 GLOBOCAN report, breast cancer is the 3rd most common cause of cancer-related mortality in the Philippines. The incidence of breast cancer in the young (≤40 years) was reported to be higher in the Philippines compared to other Asian countries. Several studies have consistently demonstrated poor survival outcomes in this age group due to its aggressiveness and unique tumour biology. However, data on survival outcomes of young Filipino breast cancer patients remains unknown in the Philippines. Methods: A retrospective study was performed involving patients with stage I–III breast cancer who underwent definitive surgery from January 2010 to December 2015 at a single-tertiary institution. Patients were grouped according to age (≤40 and >40 years old). Their clinicopathological characteristics, treatment profile and 5-year survival outcomes were analyzed. Results: A total of 524 Filipino patients (15.1% aged ≤40 years) were included. Younger patients were diagnosed at a higher stage and pathologic grade. A negative hormone receptor, high Ki67 status, and triple negative breast cancer (TNBC) subtypes were also more common among younger patients. The overall breast-conserving surgery rate was low at 8.9%. The use of adjuvant chemoradiotherapy was more common and both 5-year overall survival (OS) and disease-free survival (DFS) were lower (61.1% versus 77.1% and 31.1% versus 66.8%, respectively) in the ≤40-year-old group. In the multivariate analysis, age group, tumour size, and nodal status were significant predictors for DFS. However, only tumour size was significant for OS. Conclusion: Young Filipino breast cancer patients have demonstrated unique pathologic characteristics with associated lower survival outcomes similar to the published literature. Increasing awareness of cancer screening practices among young women, provision of equitable access to healthcare, and prompt management of breast cancer in the young are crucial.
{"title":"Young Filipino breast cancer patients have worse survival outcomes","authors":"R. V. Yap, Deanne Lou Marquez, Frances Marion De La Serna","doi":"10.3332/ecancer.2023.1639","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1639","url":null,"abstract":"Background: In the 2020 GLOBOCAN report, breast cancer is the 3rd most common cause of cancer-related mortality in the Philippines. The incidence of breast cancer in the young (≤40 years) was reported to be higher in the Philippines compared to other Asian countries. Several studies have consistently demonstrated poor survival outcomes in this age group due to its aggressiveness and unique tumour biology. However, data on survival outcomes of young Filipino breast cancer patients remains unknown in the Philippines. Methods: A retrospective study was performed involving patients with stage I–III breast cancer who underwent definitive surgery from January 2010 to December 2015 at a single-tertiary institution. Patients were grouped according to age (≤40 and >40 years old). Their clinicopathological characteristics, treatment profile and 5-year survival outcomes were analyzed. Results: A total of 524 Filipino patients (15.1% aged ≤40 years) were included. Younger patients were diagnosed at a higher stage and pathologic grade. A negative hormone receptor, high Ki67 status, and triple negative breast cancer (TNBC) subtypes were also more common among younger patients. The overall breast-conserving surgery rate was low at 8.9%. The use of adjuvant chemoradiotherapy was more common and both 5-year overall survival (OS) and disease-free survival (DFS) were lower (61.1% versus 77.1% and 31.1% versus 66.8%, respectively) in the ≤40-year-old group. In the multivariate analysis, age group, tumour size, and nodal status were significant predictors for DFS. However, only tumour size was significant for OS. Conclusion: Young Filipino breast cancer patients have demonstrated unique pathologic characteristics with associated lower survival outcomes similar to the published literature. Increasing awareness of cancer screening practices among young women, provision of equitable access to healthcare, and prompt management of breast cancer in the young are crucial.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"38 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139245285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-21DOI: 10.3332/ecancer.2023.1635
K. A. Tiscoski, J. Giacomazzi, Matheus Soares Rocha, Gustavo Gössling, Gustavo Werutsky
Breast cancer (BC) is the most prevalent cancer in women in Latin America and the Carib-bean. We compiled real-world data (RWD) on the epidemiology, diagnosis, treatment, and patient outcomes of triple-negative breast cancer (TNBC), addressing the main barriers to optimal care in Latin America. The prevalence of TNBC varies between 11% and 38.5% of all BC cases diagnosed in the region, and TNBC primarily affects young patients. Delays in BC diagnosis, with consequent advanced disease stages and barriers to access efficient therapies, particularly due to high costs, negatively impact patient outcomes. Cancer clinical trials are an opportunity to access standard and novel therapies for patients with this aggressive BC subtype and thus must be prioritised. Finally, generating RWD and cost-effectiveness studies in a region with limited resources is critical for decision-makers to define the incorporation of new technologies for the treatment of BC.
乳腺癌（BC）是拉丁美洲和加勒比海地区女性发病率最高的癌症。我们汇编了有关三阴性乳腺癌（TNBC）的流行病学、诊断、治疗和患者预后的真实世界数据（RWD），解决了拉丁美洲最佳治疗的主要障碍。在该地区确诊的所有乳腺癌病例中，TNBC 的发病率介于 11% 和 38.5% 之间，TNBC 主要影响年轻患者。BC 诊断的延误导致疾病进入晚期，以及获得高效疗法的障碍，特别是由于高昂的费用，对患者的治疗效果产生了负面影响。癌症临床试验为这种侵袭性 BC 亚型患者提供了获得标准和新型疗法的机会，因此必须优先考虑。最后，在资源有限的地区开展RWD和成本效益研究对于决策者确定将新技术用于治疗BC至关重要。
{"title":"Real-world data on triple-negative breast cancer in Latin America and the Caribbean","authors":"K. A. Tiscoski, J. Giacomazzi, Matheus Soares Rocha, Gustavo Gössling, Gustavo Werutsky","doi":"10.3332/ecancer.2023.1635","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1635","url":null,"abstract":"Breast cancer (BC) is the most prevalent cancer in women in Latin America and the Carib-bean. We compiled real-world data (RWD) on the epidemiology, diagnosis, treatment, and patient outcomes of triple-negative breast cancer (TNBC), addressing the main barriers to optimal care in Latin America. The prevalence of TNBC varies between 11% and 38.5% of all BC cases diagnosed in the region, and TNBC primarily affects young patients. Delays in BC diagnosis, with consequent advanced disease stages and barriers to access efficient therapies, particularly due to high costs, negatively impact patient outcomes. Cancer clinical trials are an opportunity to access standard and novel therapies for patients with this aggressive BC subtype and thus must be prioritised. Finally, generating RWD and cost-effectiveness studies in a region with limited resources is critical for decision-makers to define the incorporation of new technologies for the treatment of BC.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-21DOI: 10.3332/ecancer.2023.1634
F. Petracci, Cynthia Villarreal-Garza, Facundo Argañaraz, Gonzalo Gómez Abuin, José Peñaloza, Marcos Ariel Flores, Luciano Piazzoni, Cecilia Riggi, Lucía Fabiano, Lucía González, Belén Cieplinski, Sergio Rivero, Ernesto Korbenfeld, Pablo Mandó
Background: Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) improve progression free survival among patients with HER2 negative (HER2-ve) advanced breast cancer (ABC) and a BRCA1 or BRCA2 mutation compared to chemotherapy (CT). The objective of this prospective study was to evaluate the clinical benefit of PARPi treat-ment in terms of response, outcomes and survival by breast cancer type and treatment in a Latin-American
{"title":"LuciA-15 – a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes","authors":"F. Petracci, Cynthia Villarreal-Garza, Facundo Argañaraz, Gonzalo Gómez Abuin, José Peñaloza, Marcos Ariel Flores, Luciano Piazzoni, Cecilia Riggi, Lucía Fabiano, Lucía González, Belén Cieplinski, Sergio Rivero, Ernesto Korbenfeld, Pablo Mandó","doi":"10.3332/ecancer.2023.1634","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1634","url":null,"abstract":"Background: Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) improve progression free survival among patients with HER2 negative (HER2-ve) advanced breast cancer (ABC) and a BRCA1 or BRCA2 mutation compared to chemotherapy (CT). The objective of this prospective study was to evaluate the clinical benefit of PARPi treat-ment in terms of response, outcomes and survival by breast cancer type and treatment in a Latin-American","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"65 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139250955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-21DOI: 10.3332/ecancer.2023.1636
Benjamín Walbaum, José Miguel Reyes, Pablo Rodriguez, S. Muniz, L. Medina, C. Ibañez, T. Merino, Mauricio P Pinto, M. Bravo, Francisco Acevedo, José Bennett, C. Sánchez
Background: The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first-or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative (HR+/HER2-) advanced stage breast cancer (ABC). Our study compared survival rates and prognostic factors in Chilean patients that used palbociclib as first or subsequent (≥second) lines of treatment in a real-world setting. Methods: Our retrospective population-cohort study included HR+/HER2-ABC patients. We calculated 5-year OS and performed a multivariate analysis to determine prognostic factors. Results: A total of 106 patients were included. Median age was 49 years (19–86), 28.3% (30) had de novo stage IV disease; 63% received palbociclib with ET as first line, 54% of them with aromatase inhibitor over fulvestrant. Median OS for the entire cohort was 99 months and 5-year OS was 69%. Patients that received first line palbociclib had a 5-year OS of 89% versus 43% for ET monotherapy or ≥second line palbociclib ( p = 0.0062). Multivariate analysis showed that the year at diagnosis and CDKi timing (first line versus ≥second line) were significantly associated with OS. Conclusion: Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2-ABC patients.
背景：在内分泌治疗（ET）的一线或二线治疗中加入细胞周期蛋白依赖性激酶抑制剂（CDKi）可改善激素受体阳性、HER2阴性（HR+/HER2-）晚期乳腺癌（ABC）患者的无进展生存期和总生存期（OS）。我们的研究比较了在真实世界中使用帕博西尼（palbociclib）作为一线或后续（≥二线）治疗的智利患者的生存率和预后因素。研究方法我们的回顾性人群队列研究纳入了HR+/HER2-ABC患者。我们计算了5年OS，并进行了多变量分析以确定预后因素。研究结果共纳入 106 例患者。中位年龄为49岁（19-86岁），28.3%（30人）患有新发IV期疾病；63%的患者接受了帕博西尼联合ET作为一线治疗，其中54%的患者使用芳香化酶抑制剂而非氟维司群。整个组群的中位OS为99个月，5年OS为69%。接受帕博西尼一线治疗的患者的5年生存率为89%，而接受ET单药治疗或≥二线帕博西尼治疗的患者的5年生存率为43% ( p = 0.0062)。多变量分析显示，诊断年份和 CDKi 时间（一线与≥二线）与 OS 显著相关。结论我们的实际数据显示，在HR+/HER2-ABC患者中，一线CDKi+ET与≥二线CDKi+ET相比，在OS方面具有统计学意义上的显著优势。
{"title":"Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry","authors":"Benjamín Walbaum, José Miguel Reyes, Pablo Rodriguez, S. Muniz, L. Medina, C. Ibañez, T. Merino, Mauricio P Pinto, M. Bravo, Francisco Acevedo, José Bennett, C. Sánchez","doi":"10.3332/ecancer.2023.1636","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1636","url":null,"abstract":"Background: The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first-or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative (HR+/HER2-) advanced stage breast cancer (ABC). Our study compared survival rates and prognostic factors in Chilean patients that used palbociclib as first or subsequent (≥second) lines of treatment in a real-world setting. Methods: Our retrospective population-cohort study included HR+/HER2-ABC patients. We calculated 5-year OS and performed a multivariate analysis to determine prognostic factors. Results: A total of 106 patients were included. Median age was 49 years (19–86), 28.3% (30) had de novo stage IV disease; 63% received palbociclib with ET as first line, 54% of them with aromatase inhibitor over fulvestrant. Median OS for the entire cohort was 99 months and 5-year OS was 69%. Patients that received first line palbociclib had a 5-year OS of 89% versus 43% for ET monotherapy or ≥second line palbociclib ( p = 0.0062). Multivariate analysis showed that the year at diagnosis and CDKi timing (first line versus ≥second line) were significantly associated with OS. Conclusion: Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2-ABC patients.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-21DOI: 10.3332/ecancer.2023.1633
Evelyn Lilian Beas-Lozano, H. Verduzco-Aguirre, Roberto Gonzalez-Salazar, Y. Chávarri-Guerra
Breast cancer is the most common type of cancer globally. Hereditary breast cancer accounts for 10% of new cases and 4%–5% of cases are associated to pathogenic variants in BRCA1 or BRCA2 genes. In recent years, poly-adenosine-diphosphate-ribose polymerase inhibitors (PARPi) olaparib and talazoparib have been approved for patients with BRCA -associated, HER2 -negative breast cancer. These drugs have shown positive results in the early and advanced setting with a favourable toxicity profile based on the OlympiAD, OlympiA and EMBRACA phase 3 trials. However, patients included in these randomised trials are highly selected, making toxicity and efficacy in patients encountered in routine clinical care a concern. Since the approval of olaparib and talazoparib for advanced human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, several phase IIIb–IV trials, expanded access cohorts, and retrospective cohorts have provided information on the efficacy and tolerability of these treatments in patient subgroups underrepresented in the registration trials, such as older adults, patients with poor performance status, and heavily pretreated patients. The aim of this review is to present a critical review of the information regarding the use of PARPi in real-world breast cancer patients.
{"title":"Real-world data in patients with BRCA mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors","authors":"Evelyn Lilian Beas-Lozano, H. Verduzco-Aguirre, Roberto Gonzalez-Salazar, Y. Chávarri-Guerra","doi":"10.3332/ecancer.2023.1633","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1633","url":null,"abstract":"Breast cancer is the most common type of cancer globally. Hereditary breast cancer accounts for 10% of new cases and 4%–5% of cases are associated to pathogenic variants in BRCA1 or BRCA2 genes. In recent years, poly-adenosine-diphosphate-ribose polymerase inhibitors (PARPi) olaparib and talazoparib have been approved for patients with BRCA -associated, HER2 -negative breast cancer. These drugs have shown positive results in the early and advanced setting with a favourable toxicity profile based on the OlympiAD, OlympiA and EMBRACA phase 3 trials. However, patients included in these randomised trials are highly selected, making toxicity and efficacy in patients encountered in routine clinical care a concern. Since the approval of olaparib and talazoparib for advanced human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, several phase IIIb–IV trials, expanded access cohorts, and retrospective cohorts have provided information on the efficacy and tolerability of these treatments in patient subgroups underrepresented in the registration trials, such as older adults, patients with poor performance status, and heavily pretreated patients. The aim of this review is to present a critical review of the information regarding the use of PARPi in real-world breast cancer patients.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139253757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：